ThyroSeq v3, a targeted next-generation sequencing (NGS) panel evaluating point mutations, gene fusions, and copy number alterations common to thyroid cancer, identified a TFG-MET gene fusion within the tumor sample. This evidence concerns the gene MET and thyroid gland carcinoma.